unknown
Stage
1
Investors
About
Gennao Bio is a genetic medicines company developing targeted nucleic acid therapeutics using a proprietary Gene Monoclonal Antibody (GMAB) platform that employs cell-penetrating antibodies to deliver nucleic acid payloads to selected cells. The company focuses its programs on oncology and rare skeletal muscle diseases.
Explore Gennao Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.